On September 3, 2024, Edwards Lifesciences completed the sale of its Critical Care product group, a global leader in advanced patient monitoring solutions, to Becton, Dickinson and Company (BD), in a deal valued at US$4.2 billion.

Upon closing, Critical Care will operate as a separate business unit within BD's Medical segment to align with its smart connected care approach, and it will maintain its presence in Irvine, Calif. Katie Szyman, who has served as corporate vice president of Critical Care since 2015, will lead the new business unit within BD, reporting to Mike Garrison, executive vice president and president of the BD Medical segment.

Ropes & Gray, LLP served as legal counsel to BD, with Perella Weinberg Partners and Citi as financial advisors.

Cassels acted as Canadian counsel for Edwards Lifesciences with a team that included Luke Woolford, Elissa Chamberlain, Lizzie (Xinyue) Chen, Maria Constantine, Stefanie Di Francesco, and Brenda C. Swick.